Ahead Therapeutics
Preclinical-stage biotechnology company developing a nanomedicine platform to induce antigen-specific immune tolerance for autoimmune diseases. The organization focuses on liposome-based antigen delivery to reprogram pathological immune responses, advancing multiple preclinical programs toward first-in-human studies through CMC development, regulatory interactions, and public-private collaborations.
Industries
Nr. of Employees
small (1-50)
Ahead Therapeutics
Pier 07 Via Laietana 26, Entl. 08003 - Barcelona
Products
Preclinical therapeutic programs for autoimmune diseases
Platform-derived therapeutic programs using antigen-encapsulating liposomes intended to induce antigen-specific immune tolerance for multiple autoimmune indications.
Preclinical therapeutic programs for autoimmune diseases
Platform-derived therapeutic programs using antigen-encapsulating liposomes intended to induce antigen-specific immune tolerance for multiple autoimmune indications.
Services
Design and execution of preclinical studies including formulation, liposome synthesis, animal model experiments, biomarker identification and analytical characterization.
Formulation optimization, lyophilized product development and scale-up support for nanoparticle and liposome therapeutics to enable regulatory submissions.
Design and execution of preclinical studies including formulation, liposome synthesis, animal model experiments, biomarker identification and analytical characterization.
Formulation optimization, lyophilized product development and scale-up support for nanoparticle and liposome therapeutics to enable regulatory submissions.
Expertise Areas
- Antigen-specific immune tolerance
- Nanomedicine and liposome therapeutics
- Preclinical development and animal models
- CMC and formulation development (including lyophilization)
Key Technologies
- Liposome-based antigen delivery
- Nanoparticle/nanomedicine platforms
- Nanoencapsulation and supramolecular materials
- Lyophilization and formulation stabilization
News & Updates
Company representatives attended and presented at conferences including ICONAN (nanomedicine), BIO Digital, ASIT and BIOEQUITY events to support scientific dissemination and investor engagement.
Regulatory feedback from the European Medicines Agency that supports starting IND-enabling toxicology for the lead Myasthenia Gravis program and advances clinical development planning.
Award of a CPP project by the Spanish Ministry of Science and Innovation to fund preparatory activities and the First-in-Human clinical trial; project valued at €3.8 million.
Bridge financing round completed with 109% of a €1,200,000 goal secured to advance platform validation and preclinical-to-clinical transition.
Received public-private collaboration grant to support the Myasthenia Gravis first-in-human trial and biomarker identification activities.
Completed a bridge financing round at 109% of target through a biotechnology crowdfunding platform.
Company representatives attended and presented at conferences including ICONAN (nanomedicine), BIO Digital, ASIT and BIOEQUITY events to support scientific dissemination and investor engagement.
Regulatory feedback from the European Medicines Agency that supports starting IND-enabling toxicology for the lead Myasthenia Gravis program and advances clinical development planning.
Award of a CPP project by the Spanish Ministry of Science and Innovation to fund preparatory activities and the First-in-Human clinical trial; project valued at €3.8 million.
Bridge financing round completed with 109% of a €1,200,000 goal secured to advance platform validation and preclinical-to-clinical transition.
Received public-private collaboration grant to support the Myasthenia Gravis first-in-human trial and biomarker identification activities.
Completed a bridge financing round at 109% of target through a biotechnology crowdfunding platform.